Densitometry trends in postmenopausal asian women undergoing bisphosphonate treatment

Singapore Medical Journal

Volumn 52, Issue 9, 2011, Pages 677-680

  Ang, C L ^a   Singh, G ^c   Goh, A S W ^b   Shen, L ^d   Tay, B K ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b Department of Nuclear Medicine and PET ^*  (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Asian; Bisphosphonates; Bone mineral density; Postmenopausal; Women

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGE; AGED; ASIAN; BONE DENSITY; DENSITOMETRY; FEMALE; FRAGILITY FRACTURE; HUMAN; MEDICAL RECORD REVIEW; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; SINGAPORE; TREATMENT DURATION; TREND STUDY;

AGED; AGED, 80 AND OVER; BONE DENSITY; DENSITOMETRY; DIPHOSPHONATES; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RETROSPECTIVE STUDIES; SINGAPORE; TREATMENT OUTCOME;

EID: 80052972714     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22:465-75.
2. National Osteoporosis Foundation. Fast Facts on Osteoporosis [online]. Available at: www.nof.org/osteoporosis/diseasefacts.htm. Accessed August 22, 2009.
3. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359:1761-7.
4. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009; 122(Suppl 2):S14-21.
5. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-41.
6. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296:2927-38.
7. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344-52.
8. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003; 32:120-6.
9. Yan Y, Wang W, Zhu H, et al. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. J Bone Miner Metab 2009; 27:471-8.
10. Lei SF, Chen Y, Xiong DH, Li LM, Deng HW. Ethnic difference in osteoporosis-related phenotypes and its potential underlying genetic determination. J Musculoskelet Neuronal Interact 2006; 6:36-46.
11. Massart F. Human races and pharmacogenomics of effective bone treatments. Gynecol Endocrinol 2005; 20:36-44.